WeVote
Log In

Bill

Bill

S 7807

Expands the definition of epinephrine devices to include epinephrine nasal sprays

2025 Regular Session Introduced by Samra Brouk and 4 co-sponsors

New York law now recognizes epinephrine nasal sprays as emergency allergy devices equivalent to auto-injectors, expanding treatment options for anaphylaxis.

SIGNED CHAP.502
0
WeVote Research Nonpartisan
Bill Summary · S 7807

Legislative bill overview

S 7807 expands New York's definition of "epinephrine devices" to include epinephrine nasal sprays, not just traditional auto-injectors like EpiPens. The bill was signed into law on November 12, 2025, as Chapter 502, making nasal spray formulations legally equivalent to injected epinephrine for emergency allergy response purposes.

Why is this important

Epinephrine nasal sprays offer an alternative administration method that may be easier for untrained bystanders to use during anaphylactic emergencies, potentially improving response times and survival rates. This legislative change removes barriers to using and stockpiling nasal spray epinephrine in schools, workplaces, and public spaces where auto-injectors were previously the only recognized option.

Potential points of contention

  • Efficacy and medical guidance: Medical professionals debate whether nasal spray epinephrine is as effective as intramuscular auto-injectors for severe anaphylaxis, and some may resist the legal equivalence without stronger clinical evidence
  • Cost and accessibility: Nasal spray formulations may have different pricing than auto-injectors, creating questions about which option institutions will stock and whether expansion increases overall costs
  • Training and standardization: Broader device options could create confusion about proper administration, especially if different products require different techniques or if untrained responders don't know when each is appropriate

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.